Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of F-02-2-Na in Healthy Adults and Adults with Hyperuricemia
NCT07324434Phase 1Enrolling by invitation
- Sponsor
- Novagains Biopharmaceutical
- Start
- Dec 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of F-02-2-Na in hyperuricemia (18 arms), sponsored by Novagains Biopharmaceutical. Primary endpoints: Adverse Events, Concomitant Medications and 26 more. Started Dec 2025; status: enrolling by invitation.
02
Drugs
F-02-2-Na
03
Conditions
hyperuricemia
Beyond the preview
Go deeper on NCT07324434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07324434.